BRIEF-Shanghai Henlius Biotech Says Hansizhuang Approved For Marketing In Indonesia

Reuters2023-12-28

Dec 28 (Reuters) - Shanghai Henlius Biotech Inc

* HANSIZHUANG (SERPLULIMAB INJECTION)- HAS BEEN APPROVED FOR MARKETING IN INDONESIA

* PT KALBIO GLOBAL MEDIKA RECEIVED REGISTRATION CERTIFICATES ISSUED BY INDONESIA'S NATIONAL AGENCY FOR DRUG AND FOOD CONTROL

* REGISTRATION CERTIFICATES FOR APPROVAL OF COMPANY'S SELF-DEVELOPED ANTI-PD-1 MAB HANSIZHUANG

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2394717720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-12-28 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2394717720","market":"sh","top_or_hot":-1,"title":"BRIEF-Shanghai Henlius Biotech Says Hansizhuang Approved For Marketing In Indonesia","media":"Reuters","content":"<html><body><p>Dec 28 (Reuters) - Shanghai Henlius Biotech Inc</p><p> :</p><p>   * HANSIZHUANG (SERPLULIMAB INJECTION)- HAS BEEN APPROVED FOR MARKETING IN INDONESIA</p><p>   * PT KALBIO GLOBAL MEDIKA RECEIVED REGISTRATION CERTIFICATES ISSUED BY INDONESIA'S NATIONAL AGENCY FOR DRUG AND FOOD CONTROL</p><p>   * REGISTRATION CERTIFICATES FOR APPROVAL OF COMPANY'S SELF-DEVELOPED ANTI-PD-1 MAB HANSIZHUANG</p><p>Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Shanghai Henlius Biotech Says Hansizhuang Approved For Marketing In Indonesia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Shanghai Henlius Biotech Says Hansizhuang Approved For Marketing In Indonesia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-28 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 28 (Reuters) - Shanghai Henlius Biotech Inc :   * HANSIZHUANG (SERPLULIMAB INJECTION)- HAS BEEN APPROVED FOR MARKETING IN INDONESIA   * PT KALBIO GLOBAL MEDIKA RECEIVED REGISTRATION CERTIFICATES ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2394717720","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2394717720","pubTimestamp":1703767642,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 28  - Shanghai Henlius Biotech Inc :   * HANSIZHUANG - HAS BEEN APPROVED FOR MARKETING IN INDONESIA   * PT KALBIO GLOBAL MEDIKA RECEIVED REGISTRATION CERTIFICATES ISSUED BY INDONESIA'S NATIONAL AGENCY FOR DRUG AND FOOD CONTROL   * REGISTRATION CERTIFICATES FOR APPROVAL OF COMPANY'S SELF-DEVELOPED ANTI-PD-1 MAB HANSIZHUANGFurther company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"复宏汉霖生物科技有限公司称汉思庄获准在印尼上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9},"content_text":"Dec 28 (Reuters) - Shanghai Henlius Biotech Inc :   * HANSIZHUANG (SERPLULIMAB INJECTION)- HAS BEEN APPROVED FOR MARKETING IN INDONESIA   * PT KALBIO GLOBAL MEDIKA RECEIVED REGISTRATION CERTIFICATES ISSUED BY INDONESIA'S NATIONAL AGENCY FOR DRUG AND FOOD CONTROL   * REGISTRATION CERTIFICATES FOR APPROVAL OF COMPANY'S SELF-DEVELOPED ANTI-PD-1 MAB HANSIZHUANGFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2394717720"}